Mary Thistle Buys Shares of Cullinan Therapeutics

Mary Thistle recently bought 25,319 shares of Cullinan Therapeutics, Inc. (NasdaqGS: CGEM) on June 16, 2026. The transaction was not part of a pre-planned trading program. Shares of Cullinan Therapeutics were trading at $14.44 at the time.

Other Institutional Activity in Cullinan Therapeutics

In recent institutional activity, BlackRock, Inc. increased its holdings by 49,670 shares, bringing its total to 4,449,966 shares valued at approximately $63.2 million. Meanwhile, State Street Corp significantly boosted its stake by 346,777 shares, reaching a total of 2,544,115 shares worth about $36.2 million. Other notable holders like LYNX1 Capital Management LP and MPM BioImpact LLC maintained their positions, holding 8,963,500 and 7,648,268 shares, respectively.

Cullinan Therapeutics Stock Snapshot

Cullinan Therapeutics trades on the NasdaqGS under the ticker CGEM. The stock is currently priced at $14.44, with a market capitalization of approximately $887.5 million. It has a forward P/E ratio of -5.71, reflecting its lack of profitability. The stock's 52-week range spans from $5.68 to $16.74. The company maintains a strong liquidity position with a current ratio of 10.28 and a quick ratio of 10.09.

Insider Buying and Selling at Cullinan Therapeutics, Inc.

On June 16, 2026, several insiders, including Doyle Mittie, Mary Thistle, David Meek, Andrew Allen, Stephen Webster, and Anthony Rosenberg, purchased shares of Cullinan Therapeutics. Each insider acquired 25,319 shares, except for Doyle Mittie and Andrew Allen, who each bought 21,781 shares. None of these transactions were part of a pre-planned trading program.

Analysts Set New Price Targets

Analyst activity remains bullish on Cullinan Therapeutics. On June 11, 2026, Wedbush reiterated its buy rating with a price target of $37. BTIG also reiterated a buy rating with a target of $38 on April 29, 2026. The consensus among 11 analysts is a strong buy, with a target mean price of $31.55.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. Founded in 2016, the company focuses on developing therapies for autoimmune diseases and cancer. Its pipeline includes several bispecific T cell engagers in clinical trials, such as CLN-978 and Velinotamig, as well as an EGFR inhibitor named Zipalertinib. The company collaborates with partners like Chongqing Genrix Biopharmaceutical Co., Ltd and Taiho Pharmaceutical Co., Ltd.

Bottom Line

Mary Thistle's recent purchase of shares in Cullinan Therapeutics highlights ongoing interest in the company's potential. Investors watch insider transactions closely as they can signal confidence in a company's outlook. While the stock is currently trading below its 52-week high, it remains a focus of analysts who maintain a strong buy rating. As always, it's essential to remember that insider buying and analyst ratings are just part of the broader picture.